News Articles Tagged: Hexamethylene Amiloride

Hexamethylene Amiloride: A New Frontier in Targeting Intracellular pH and Cancer Growth

Explore how Hexamethylene Amiloride (CAS 1428-95-1) effectively targets intracellular pH regulation, impacting cancer cell proliferation and offering new therapeutic avenues.

Hexamethylene Amiloride: In Vivo Anti-Myeloma Efficacy and Therapeutic Potential

Examine the in vivo effectiveness of Hexamethylene Amiloride (CAS 1428-95-1) against multiple myeloma, exploring its therapeutic potential and implications for combination treatments.

The Role of TFE3 in Hexamethylene Amiloride-Induced Cancer Cell Death

Investigate the critical role of transcription factor TFE3 in Hexamethylene Amiloride's ability to induce lysosome-mediated cell death in cancer cells.

Hexamethylene Amiloride: A Versatile Inhibitor in Cancer Research and Drug Development

Discover the multifaceted roles of Hexamethylene Amiloride (CAS 1428-95-1) as an NHE1 inhibitor and its impact on cancer cell survival, proliferation, and drug resistance.

Unlocking Cancer's Weakness: Hexamethylene Amiloride and Lysosome-Targeted Therapy

Delve into the molecular mechanisms of Hexamethylene Amiloride (CAS 1428-95-1), revealing its role in triggering lysosome-mediated cell death and its implications for innovative cancer treatments.

Hexamethylene Amiloride: A New Hope for Carfilzomib-Resistant Multiple Myeloma

Explore how Hexamethylene Amiloride (CAS 1428-95-1) is revolutionizing multiple myeloma treatment by overcoming carfilzomib resistance and inducing lysosome-mediated cell death. Learn more.